Challenges in sexual medicine

  title={Challenges in sexual medicine},
  author={Selim Cellek and Annamaria Giraldi},
  journal={Nature Reviews Urology},
The sexual medicine field has been in mode of revolution until recently. Like all other fields of biomedical research, the economic situation around the world has had a negative impact on the field's momentum—research funding bodies, regulatory bodies and pharmaceutical companies seem to have placed sexual medicine in their low-priority list. But this is not the only challenge the field is facing. The successful development of phosphodiesterase type 5 (PDE5) inhibitors for treatment of erectile… 
The only available certification for sexual medicine: The Fellow of the European Committee Sexual Medicine (FECSM)
The MJCSM has developed the first endorsed postgraduate curriculum for Sexual Medicine that have been approved by the UEMS as European Standards in Medical Training for sexual medicine.
A Multiple Timepoint Pre-post Evaluation of a ‘Sexual Respect’ DVD to Improve Competence in Discussing Sex with Patients with Disability
Overall, the DVD intervention had a significant and positive impact on nursing students’ self-reported knowledge, confidence, comfort and willingness levels and emphasises the importance of a proactive approach to addressing sexuality issues.
Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial
In premenopausal women with female sexual dysfunctions, self-administered, as desired, subcutaneous BMT was safe, effective, and well tolerated (NCT01382719).
Survey on the experiences, attitudes, and training needs of Australian healthcare professionals related to sexuality and service delivery in individuals with acquired brain injury.
Inadequate education and training, not knowing whose role it is and when to raise the topic, and the view that individuals with ABI will ask for the information were all identified as key barriers contributing to poor sexuality management after ABI.
Talking about sex after traumatic brain injury: perceptions and experiences of multidisciplinary rehabilitation professionals
Rehabilitation professionals’ perceptions and experiences of discussing sexuality with service-users who have had a TBI are explored, suggesting that a more proactive approach to addressing sexuality issues be taken by incorporating sexuality into assessments and by having sexuality information available for service- users.
Talking about sex after Traumatic Brain Injury : perceptions and experiences of professionals
In order that sexuality becomes accepted as an integral part of holistic rehabilitation, it is recommended that a more proactive approach is taken and sexuality is incorporated into assessments, and that written information is available for service-users.
Development and Syntheses of Flibanserin (Addyi®) - "the Female Viagra®"
An overview of the drug development, mechanism of action, synthetic routes to the active principle and finally the controversial approval process of Addyi® (flibanserin) is presented.


Highlights from the history of sexual medicine.
The term sexual medicine was established around 1970, most likely in Europe, and subsequently resulted in a new worldwide academic and clinical speciality.
Emerging tools for erectile dysfunction: a role for regenerative medicine
The identification of a large population of “difficult-to-treat” patients has triggered researchers to identify novel treatment approaches, which focus on cure and restoration of the underlying cause of ED.
Female sexual dysfunction
  • R. Segraves
  • Psychology, Medicine
    European Psychiatry
  • 2007
Animal models in urological disease and sexual dysfunction
This review describes some of the animal models that may be used to discover safe and effective medicines with which to treat sexual dysfunction and SUI and OAB, characterised by high prevalence, a growing ageing population and a strong desire from sufferers and physicians for more effective treatment options.
Pharmacotherapy for women's sexual dysfunction
  • R. Basson
  • Medicine, Biology
    Expert opinion on pharmacotherapy
  • 2009
Results of sexual benefit from local administration of dihydroepiandrosterone allowing intracellular production of oestrogen and testosterone in genital tissues post menopause seem promising.
The birth of sexual medicine: Paolo Mantegazza as pioneer of sexual medicine in the 19th century.
  • V. Sigusch
  • Medicine, Psychology
    The journal of sexual medicine
  • 2008
It was evident that Paolo Mantegazza possesses the whole width of modern sexual-medical activities, from laboratory experiments to cultural-critical and ethnological studies, and his books, translated in many languages, were almost completely forgotten after his death.
The testosterone patch for women
  • S. Kingsberg
  • Medicine, Biology
    International Journal of Impotence Research
  • 2005
Editor's Note: Has the FDA discriminated against female sexual dysfunction by not endorsing Procter & Gamble's (P&G) Intrinsa? Has the pendulum swung so far to the right that drugs for sexual
The future is today: emerging drugs for the treatment of erectile dysfunction
This review discusses clinical and preclinical evidence supporting various emerging compounds that regulate penile erection both centrally and peripherally and suggests a tailored approach may include combination of various emerging drugs to enhance efficacy in difficult-to-treat patients.
Psychosocial factors and therapeutic approaches in the context of sexual history taking in men: a study conducted among Swiss general practitioners and urologists.
Analyzing to what extent Swiss GPs and urologists have a psychosocial orientation in SHT and what therapeutic options they focus on when confronted with male sexual dysfunction justifies establishing guidelines and training resources related to SHT in Switzerland.
Flibanserin: A Potential Treatment for Hypoactive Sexual Desire Disorder in Premenopausal Women
An overview of the pharmacology, clinical efficacy and safety of flibanserin is presented, a 5-HT1A agonist/5-HT2A antagonist that is under investigation as a treatment for HSDD in women.